Page last updated: 2024-09-05

sb 203580 and fenretinide

sb 203580 has been researched along with fenretinide in 2 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(fenretinide)
Trials
(fenretinide)
Recent Studies (post-2010) (fenretinide)
3,48941,13788193215

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Gui, S; Huang, D; Liu, H; Shao, D; Wang, Y; Wei, W; Zhang, L; Zhou, Q1

Other Studies

2 other study(ies) available for sb 203580 and fenretinide

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Fenretinide inhibits the proliferation and migration of human liver cancer HepG2 cells by downregulating the activation of myosin light chain kinase through the p38‑MAPK signaling pathway.
    Oncology reports, 2018, Volume: 40, Issue:1

    Topics: Apoptosis; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Fenretinide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Imidazoles; Liver Neoplasms; Myosin-Light-Chain Kinase; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Signal Transduction

2018